“Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA).”
All entries for: Multiple
November 2, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
October 26, 2023
Bristol Myers Squibb
Negative Outlook
Princeton, NJ
10,001-50,000 employees
10001-50000 employees
“On June 16, 2023, BMS filed a lawsuit against the U.S. Department of Health & Human Services and the Centers for Medicare & Medicaid Services, et al., challenging the constitutionality of the drug-pricing program in the IRA. That program requires pharmaceutical companies, like BMS, under the threat of significant penalties, to sell certain of their medicines at government-dictated prices”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
August 10, 2023
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
August 9, 2023
Pfizer
Neutral Outlook
New York, NY
50,001+ employees
50001+ employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 8, 2023
Recursion Pharmaceuticals
Neutral Outlook
Salt Lake City, UT
201-500 employees
201-500 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 8, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
August 3, 2023
Alnylam
Negative Outlook
Cambridge, MA
1,001-5,000 employees
1001-5000 employees
Disease Area: Multiple
Drug Type: Biologic
August 3, 2023
Regeneron
Neutral Outlook
Tarrytown, NY
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
August 3, 2023
Acadia Pharmaceuticals
Negative Outlook
San Diego, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple
Drug Type: Small Molecule
August 3, 2023
Vir Biotechnology
Discontinued Drug, Discontinued Research
San Francisco, CA
501-1,000 employees
501-1000 employees
“Vir Biotechnology is narrowing its focus. Sitting on $1.9 billion, the infectious disease specialist has decided to stop work on its innate immunity small-molecule platform as part of its efforts to ‘judiciously allocate’ its capital.
San Francisco-based Vir was already primarily focused on biologics, making its name through work on the anti-SARS-CoV-2 antibody Xevudy and advancing a pipeline featuring other modalities including T-cell vaccines and siRNAs. But small molecules were in the mix, too, with the biotech identifying the modality as part of its plans for a multi-respiratory hepatitis B cure and response to COVID-19…
‘We are taking measures to continuously evaluate and judiciously allocate this capital to maximize value for our shareholders,’ De Backer said. ‘As part of this process and under my leadership, we made the decision to phase out our small molecule platform. This is the first step as we continue to advance our core capabilities and scientific programs.'”
2 Discontinued Drugs: unnamed multi-respiratory hepatitis B drug (small molecule), unnamed COVID-19 drug (small molecule)
2 Discontinued Research Programs
Disease Area: Multiple
Drug Type: Small Molecule
